Adaptive Biotechnologies Corp (ADPT) President and COO Julie Rubinstein exercised options for 11,881 shares at $12.14 per share on each of October 6, 7 and 8, 2026, and reported sales on each date. October 6 sale lots were 9,381 shares at a weighted-average $27.36, 1,100 at $28.21, 901 at $29.71 and 499 at $30.53 per share. She sold 11,881 shares at a weighted-average $26.40 on October 7 and 11,881 at $25.66 on October 8. The transactions were under a Rule 10b5-1 plan adopted November 18, 2025.
Adaptive Biotechnologies Corp Chief Commercial Officer, MRD Susan Bobulsky sold 6,444 shares of common stock at $30 per share on October 6, 2026. The sale was made under a Rule 10b5-1 trading plan adopted on December 16, 2025. She directly held 389,350 shares after the transaction.
Adaptive Biotechnologies Corp officer Susan Bobulsky reported a proposed sale of 6,444 common shares, with an aggregate market value of $192,288.96 and an approximate sale date of October 6, 2026. The shares were acquired upon the vesting of restricted stock units during the period from March 4, 2023, through March 4, 2024.
Her past-three-month sales identified as 10b5-1 sales were 5,000 shares on July 16, 2026; 1,299 shares on July 30, 2026; 3,000 shares on August 10, 2026; and 1,195 shares on September 15, 2026. The issuer’s common shares outstanding are listed as 159,595,842.
Adaptive Biotechnologies Corp (ADPT) President and COO Julie Rubinstein exercised options covering 11,881 shares on each of October 1, 2 and 5, 2026, at an exercise price of $12.14 per share, and sold 35,643 shares over those dates. The sales comprised 6,081 shares at a weighted average price of $27.57 and 5,800 at $28.56 on October 1; 11,881 at $28.13 on October 2; and 6,699 at $28.82 and 5,182 at $29.67 on October 5. All transactions were effected pursuant to a Rule 10b5-1 trading plan adopted November 18, 2025; the options were fully vested and exercisable.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo exercised three stock-option tranches on October 1, 2026, for 8,038 shares at an $8.46 exercise price, 9,377 shares at $3.99, and 9,377 shares at $8.12; corresponding common-stock acquisitions were reported. On the same date, Lo sold 8,094 shares at a weighted-average price of $27.52 and 18,698 shares at a weighted-average price of $28.61. Both sale prices were weighted averages within ranges stated in the transaction footnotes. The transactions were made under a Rule 10b5-1 trading plan adopted September 15, 2025.
Adaptive Biotechnologies Corp. (ADPT) officer Julie Rubinstein gave notice of an intended sale of 379,777 common shares. The notice says she will receive the shares through stock-option exercises over the next three months, with acquisition and payment dates tied to the exercise and sale dates.
Adaptive Biotechnologies Corp (ADPT) reported that Chief People Officer Francis Lo exercised employee stock options for 105,560 shares of common stock on September 16, 2026, at exercise prices between $3.99 and $12.14 per share, and on the same day sold 115,406 shares of common stock in market transactions.
The sales, made at weighted average prices of $28.02 and $28.57 per share within disclosed price ranges, were effected pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2025. An additional 2,500 shares are reported as indirectly held through Lo’s spouse.
Adaptive Biotechnologies Corp (ADPT) reported that Chief Commercial Officer, MRD, Susan Bobulsky sold 1,195 shares of common stock on September 15, 2026, at a price of $27.00 per share in an open-market or private transaction. After this sale, she held 395,794 shares directly.
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Susan Bobulsky on December 16, 2025.
Adaptive Biotechnologies Corp (ADPT) officer Francis Lo has filed a notice to sell 142,198 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $3,793,842.64 as of September 16, 2026.
The planned sales include 132,352 shares to be received from the exercise of stock options on September 16, 2026 and 9,846 shares from restricted stock units vesting on March 4, 2026. The notice states that the securities to be sold were and will be received upon option exercises, with acquisition and payment dates matching the respective exercise or sale dates.
Adaptive Biotechnologies Corp (ADPT) received a Rule 144 notice from officer Susan Bobulsky covering a planned sale of 1,195 shares of common stock through Morgan Stanley Smith Barney LLC. The shares relate to Restricted Stock Units granted on March 4, 2024, and the issuer’s common stock trades on NASDAQ.
The notice also lists prior sales under a Rule 10b5-1 trading plan over the past three months, including multiple transactions in June, July, and August 2026, each disclosing shares sold and aggregate dollar proceeds.